Leslie Trigg Sells 3,361 Shares of Outset Medical (NASDAQ:OM) Stock

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 3,361 shares of the company’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $3.35, for a total transaction of $11,259.35. Following the transaction, the chief executive officer owned 102,342 shares of the company’s stock, valued at approximately $342,845.70. This trade represents a 3.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Leslie Trigg also recently made the following trade(s):

• On Wednesday, January 21st, Leslie Trigg sold 2,120 shares of Outset Medical stock. The shares were sold at an average price of $5.05, for a total value of $10,706.00.
• On Tuesday, January 20th, Leslie Trigg sold 11,794 shares of Outset Medical stock. The shares were sold at an average price of $5.12, for a total value of $60,385.28.
• On Wednesday, January 7th, Leslie Trigg sold 1,795 shares of Outset Medical stock. The stock was sold at an average price of $4.27, for a total value of $7,664.65.

Outset Medical Price Performance

Shares of OM opened at $3.53 on Friday. The stock has a 50 day moving average price of $4.33 and a 200 day moving average price of $8.99. Outset Medical, Inc. has a one year low of $3.10 and a one year high of $21.98. The company has a debt-to-equity ratio of 0.76, a quick ratio of 5.77 and a current ratio of 6.67. The stock has a market capitalization of $64.63 million, a price-to-earnings ratio of -0.52 and a beta of 2.08.

Institutional Trading of Outset Medical

Several hedge funds have recently made changes to their positions in the company. BML Capital Management LLC acquired a new stake in shares of Outset Medical during the 4th quarter worth approximately $2,015,000. Pura Vida Investments LLC increased its stake in Outset Medical by 8,482.4% during the second quarter. Pura Vida Investments LLC now owns 429,120 shares of the company’s stock worth $8,243,000 after acquiring an additional 424,120 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in Outset Medical during the third quarter worth $5,324,000. Geode Capital Management LLC raised its position in Outset Medical by 955.9% in the second quarter. Geode Capital Management LLC now owns 415,552 shares of the company’s stock valued at $7,984,000 after purchasing an additional 376,196 shares during the period. Finally, Millennium Management LLC lifted its stake in shares of Outset Medical by 165.8% in the 3rd quarter. Millennium Management LLC now owns 421,409 shares of the company’s stock valued at $5,950,000 after purchasing an additional 262,874 shares during the last quarter.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of Outset Medical from a “hold” rating to a “sell” rating in a research note on Sunday, February 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Outset Medical in a report on Monday, December 29th. Stifel Nicolaus lowered their target price on Outset Medical from $14.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, January 7th. Royal Bank Of Canada restated a “sector perform” rating and issued a $7.00 price target on shares of Outset Medical in a research report on Wednesday, December 17th. Finally, BTIG Research reduced their price objective on Outset Medical from $17.00 to $15.00 and set a “buy” rating on the stock in a research report on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.